Indevus Pharmaceuticals Inc. (IDEV)
Loading...
Symbols:
IDEV Forum Topics
- All Comments on IDEV
- General Discussion on IDEV
- Indevus: Making Big Gains with Approval for Its New Drug [view article]
- Indevus Pharmaceuticals: Nebido Has Lost Its Libido [view article]
- Jim Cramer's Mad Money Lightning Round, 10/8/07: Buy China Digital [view article]
- Screening for Potential Buyout Targets [view article]
loading ...Recent IDEV Articles
- Indevus: Making Big Gains with Approval for Its New Drug
- Indevus Pharmaceuticals: Nebido Has Lost Its Libido
- Wednesday's Options Report: Ikon, IDEV, Verigy, WFC, JNY, PPCO
- Screening for Potential Buyout Targets
- Biotech Day In Review: MedImmune Puts Itself Up For Sale
- Indevus' Sanctura XR Proves Attractive Beside Competitor 'Speed Bumps'
- Biotech Day in Review: Biosite Takes $85 Offer from Beckman Coulter
- Indevus Buyout of Valera to Grow Earnings
- Full List of Articles »
Trading Center
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »
Indevus: Making Big Gains with Approval for Its New Drug [view article]
Thanks for the info Mr. Snyder. Do you think the price will rise back to the $7 to $8 range now or will it settle less on this good news? I own some Jan options in this and was pleasantly surprised by this dose of double good news. It is rare in this market to get excited about anything, but with an over 100% gain in a day, its hard not too. ReplyIndevus Pharmaceuticals: Nebido Has Lost Its Libido [view article]
Rocco: was the FDA devoid of “commercial zeal” when they shot down Provenge with panelists who had “conflicts of interest” ? Spare us the yada yada of the FDA mission statement. Your in CYA mode and everyone knows it.Reply
Indevus Pharmaceuticals: Nebido Has Lost Its Libido [view article]
the fda as not yet come to any decission on this as yet. it was only the companies impression that they might delay for a new safetystudy. The safety issues are benign and well known therefore there
is no need for a new study. Reply
Indevus Pharmaceuticals: Nebido Has Lost Its Libido [view article]
it is amazing how a group of people such as the FDA control the fate of medical science and innovation in a country like ours .it is a shame I feel as if I am in a third world country when I hear their verdicts on some of these drugs this is more of a dictatorship I bet you some of the panelists enjoy seeing some people suffering,if this continues the US will loose the edge of innovation to other countries ReplyJohnson
Indevus Pharmaceuticals: Nebido Has Lost Its Libido [view article]
This FDA decision limits 4 to 5 million American men suffering from Hypogonadism to the use gel/patch/pellet.Pellet - most invasive requires surgery. The FDA approved an operation as it is safer than an injection?
Gels - least invasive daily applications with fluctuation even when they remember to apply everyday. The FDA approved self medication over medical supervision?
What does Europe and the 70 countries worldwide who administer long-acting depot formulation understand that the FDA does not?
Low testosterone has huge medical, financial, social and emotional costs:
diabetes
coronary artery disease
hypothyroidism
hyperlipidemia.
increased body fat
poor concentration and memory
reduced bone and muscle mass
diminished libido
erectile dysfunction
decreased physical performance
The FDA wants to impose a 2 year delay because improper injection caused reversible shortness of breath and coughing?
Excellent to read the FDA’s integrity is being questioned not just by congressional hearings but by the public for which they suppose to serve and protect!
Reply
ul
Indevus Pharmaceuticals: Nebido Has Lost Its Libido [view article]
The simple fact is that the FDA is out of control. There is simply no logical reason for such absurd indications, as apparently is the case, to be coming from FDA. The product has been available in Europe from 2003, the minor potential side effects are well documented, easily dealt with, and could be adequately addressed with appropriate labeling warnings. These fascists big brother types would no doubt ban aspirin were it presented to them for approval at this time. At least in this case people are not dying needlessly due to the FDA's decision...not so for end-stage prostate cancer victims denied Dendreon's Provenge.Reply
Indevus Pharmaceuticals: Nebido Has Lost Its Libido [view article]
While I agree that the FDA's decision was ludicrous I don't agree that it merits being called a "potential company-destroying two-year approval delay"...the company is generating substantial and increasing revenues from other products and has others well along in phase II and III...I really didn't think that nebido was all that worthy of development to begin with...with competing testosterone depot products I wondered what the profit and revenue potential would be...I also think they should finally dump that absurdity "pagoclone" -- the world doesn't need another benzodiazepene...compa... the company to the recently bought out TRCA I think IDEV should be north of $7 even without nebido. ReplyTurner
Indevus Pharmaceuticals: Nebido Has Lost Its Libido [view article]
While (interested reader) is correct that Testopel is a long acting testosterone pellet, it involves a surgical procedure to implant:"The implant procedure consists of a small incision through which a trocar and cannula are inserted. The pellets are inserted through the cannula, and then the cannula is withdrawn. The incision is then closed with a Steri-Strip, and pressure is applied until bleeding stops, and the area is then covered with a dressing. We have not had any major problems in terms of side effects from this procedure. Some expertise is required in terms of placing the pellets so that underlying structures are not traumatized." Quote from the excellent website Human Health Solutions. (www.humanhealthsolutio...)
I feel that a medicine that involves a surgical procedure to take is not the same as one that can be given with an injection; that is why I did not include the scantly used Testopel in my article. Thank you all for your comments and allowing me to clarify my article. Reply
Verducci
Indevus Pharmaceuticals: Nebido Has Lost Its Libido [view article]
Steve,The FDA, by design, exercises extreme caution with respect to their evaluation and approval of drugs since the health of every American is potentially at risk. Additionally, their judgment is devoid of the commercial zeal that investors have about a particular product. If we had to shoulder the responsibility of evaluating a drug and observing the consequences of prematurely approving a drug that should have had a more rigorous screening, I truly believe that most would err on the side of caution.
There are presently testosterone products that are available that are delivered through safer delivery systems (i.e. transdermally). What I would be more concerned with is the potential that androgen therapy has for increased risk of benign enlargement of the prostate or that it may promote the growth of existing cancer of the prostate. However, the once every three month injectable regimen does confer a patient-centric advantage in terms of convenience.
Although the indication for Nebido is for hypogonadism (Common effects of hypogonadism include decreased sexual desire, erectile dysfunction, muscle loss and weakness, depression, as well as an increased risk of osteoporosis), the name Nebido suggests that its primary function will be to elevate the libido in men. I do believe that the phosphodiesterases (e.g. Viagra, Levitra and Cialis) will still maintain their market preeminence and support by physicians since they have specificity for the primary problem associated with erectile dysfunction (ED) without the potential of increasing the risk associated with androgens.
If the parent company continues on its track of developing innovative compounds, it is likely that a large pharma or biotech company will either partner with them or enter into some equity agreement.
Ciao,
Reply
ader
Indevus Pharmaceuticals: Nebido Has Lost Its Libido [view article]
Some of the facts here are not correct - Nebido is not the only long acting product in the USA. Testopel, an implantable pellet (available from Slate Pharmaceuticals) is approved and delivers testosterone for 3-6 months. ReplyIndevus Pharmaceuticals: Nebido Has Lost Its Libido [view article]
Seems to me that big PHARMA doesn't need competition for its ED products.Seriously, what else could it be? I'm 66 yrs old and wish there was something available to deter the muscle loss I'm experiencing form low testosterone.
I'm waiting for the CEO of IDEV to make a comment on this.
I do hold stock in IDEV.
Reply
General Discussion on IDEV
I bought more IDEV yesterday (June 4th 2008) at what I think is a fantastic price!!!! There was a huge exit or more likely speculation? Very high volume. I buy for the long haul and IDEV has a GREAT pipe line ...too good to ignore after on bogus FDA ruling. I think it's a fantastic buy right NOW !!On Apr 06 05:18 AM SeekingAlpha Editors wrote:
> Is this a buy or a sell? Reply
Editors
General Discussion on IDEV
Is this a buy or a sell? ReplyJim Cramer's Mad Money Lightning Round, 10/8/07: Buy China Digital [view article]
10/24 OCT.3RD JIM CRAMER SAY I WANT YOU IN NSTK NOT ISIS! NSTK HAS BECOME A WHITE ELEPHANT FOR HIM AFTER 36 TOUTS AND HE LOOKS EVEN MORE FOOLISH DOWNGRADING ISISBECAUSE IT HAS CONTINUED TO PERFORM BETTER THAN NSTK TO DATE, AND WILL HAVE BETTER EARNINGS THAN NSTK ON NOV.8TH AND LASTLY WILL MORE THAN LIKELY HAVE A SPECTACULAR DRUG APPROVED BY THE FDA BY 3RD WEEK OF NOVEMBER.
NSTK WILL CONTINUE TO GO DOWN BECAUSE THE YEAR END EARNINGS REPORT IS WORST OF ALL COME MARCH 2008! GIVE IT UP CRAMER, STOP BEATING THE NSTK DRUMS! Reply
Jim Cramer's Mad Money Lightning Round, 10/8/07: Buy China Digital [view article]
TUESDAY,OCT.10TH ONCE AGAIN CRAMER TOUTS NSTK!SEEKINGALPHA LEFT OUT HIS 9/26 LIGHTNING ROUND WHEN HE SAID I LIKE NSTK AT $12 DOLLARS, DON'T BUY!
EITHER WAY CRAMER HAS NOW TOUTED NSTK A TOTAL OF 34 TIMES SINCE MARCH 16TH, 2007.
DO YOU THINK HE IS OBSESSED WITH THIS STOCK?
IS THERE A MOTIVE TO HIS MADNESS?
DOES THE SECURITIES&EXCHANG... COMMISSION CARE?
WILL THE MARCH 2008 YEAR END EARNINGS REPORT CHOP THIS STOCK PRICE BACK TO NEW LOWS?
WILL SEEKING ALPHA EVER UPDATE THEIR WEB SITE SINCE THE LAST PIECE OF NEWS ON IT IS DATED APRIL 2007?
WILL SEEKING ALPHA REPORT ON COMPANIES SUCCEEDING IN
RNAI WHO ARE IN THE FOREFRONT COMPARED TO NSTK?
THERE IS NO FAIR BALANCE RE:NSTK ON THIS SITE, THEREFORE I WANTED TO STATE MY OPINION! Reply